Vector Science
Beyond's analysis on Vector Science
- — Vector Science and Therapeutics hires RedChip for investor relations and awards stock options to boost market presence
- — Vector Science & Therapeutics posts first quarterly results as a public company and outlines August 2026 peptide‑manufacturing revenue start
Recent news mentioning Vector Science
- — Vector Science and Therapeutics Corp. Enters Into an Investor Relations Agreement and Grants Options
- — Vector Science & Therapeutics (TSXV: PAIN) Begins Peptide Production as First Suite at LyoGenesis Manufacturing Comes Online
- — Vector Science and Therapeutics Corp. (TSXV: PAIN) Files Provisional Patent Application on Integrated Platform for Orthopedic Tissue Regeneration Using Peptides
- — Vector Science and Therapeutics Corp. Signs Amended, 10-Year Manufacturing and Testing Agreement with LyoGenesis Holdings
- — Vector Science & Therapeutics Corp., LyoGenesis Plus and Wynn Pharmaceuticals Announce Strategic Collaboration to Develop and Manufacture Critical Care Medical Products